PDCD1 and non-small cell lung carcinoma: clinical trials are underway, in which various chemioradiotherapy regimens and radiotherapy methods (usually stereotactic radiotherapy) are used in combination with anti-PD-1 (nivolumab, pembrolizumab) or anti-PD-L1 (atezolizumab, durvalumab, avelumab) antibodies in early stage NSCLC patients (especially if surgery is not available) or locally advanced NSCLC patients [11].